A Phase 2 interventional study of BIBF 1120 and sunitinib in Carcinoma, Renal Cell, sponsored by Boehringer Ingelheim. Completed at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-19.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Carcinoma, Renal Cell with a site in Ukraine — none open to participants now, 6 under way, 5 of them phase 3. Carcinoma, Renal Cell · Ukraine.
Among the 22 studies in Carcinoma, Renal Cell with a site in Ukraine, this one is the 19th largest by enrollment, is one of 2 that started in 2009, is one of 5 in phase 2, and was the 10th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →None of the 22 studies in Carcinoma, Renal Cell with a site in Ukraine is open now. The open studies under Carcinoma, Renal Cell, anywhere →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 16
First in 2003; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 275 across the 22 interventional studies. Of the 16 that completed or were terminated, 14 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 1 study filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
1 of the studies in Carcinoma, Renal Cell with a site in Ukraine that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Carcinoma, Renal Cell with a site in Ukraine, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Compare safety and efficacy of BIBF 1120 versus sunitinib in patients with advanced RCC and to investigate the effects of BIBF 1120 on the heart rate (HR) corrected QT interval (QTcF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-marketed substance: Twice daily oral doses of 200mg BIBF 1120 given continuously.
Drug: BIBF 1120
Marketed substance: Once a day oral doses of 50mg sunitinib given in repeated 6 week cycles: 4 weeks active, 2 weeks rest.
Drug: sunitinib
Probability Rates of Progression-free Survival at 9 Months
Progression free survival rate at 9 months is the estimated probability of being alive and not having progressive disease at 9 months after randomisation. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria version 1.1 (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.
Time frame: At 9 months after randomisation.
Time-matched Change From Baseline to Day 15 in QTcF (QT Interval Corrected by the Fridericia Formula) at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 15 in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 15 obtained at time t minus baseline QTcF measurement at time t. 0 h is 5 min prior to dosing on Day 15. Time-matched change from baseline to Day 15 in QTcF was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h,1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 15 of are reported.
Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Progression Free Survival (PFS)
Progression free survival (PFS) from randomisation to the occurrence of disease progression (by RECIST Version 1.1) or death, whichever occurred first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates.
Time frame: From the start of study until the cut-off date for 3 year efficacy analysis, up to 3 years.
Objective Response According to RECIST Criteria
Objective response was defined as complete response (CR, the disappearance of all target and non-target lesions and no new lesions) or partial response (PR, at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum of the longest diameters and no new lesions) as determined by RECIST Version 1.1. Numbers of participants with objective response are reported. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.
Time frame: From the start of study until the cut-off date for 3 year efficacy analysis, up to 3 years.
Duration of Objective Response
Duration (months) of objective response was measured from the time of first objective response to the time of disease progression (by RECIST Version 1.1) or death, whichever occurred first. Objective response was defined as complete response (CR, the disappearance of all target and non-target lesions and no new lesions) or partial response (PR, at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum of the longest diameters and no new lesions) as determined by RECIST Version 1.1. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates.
Time frame: From the time of first objective response to the time of disease progression or death (whichever comes first), up to 3 years.
Overall Survival
Overall survival was calculated as the time (months) from randomisation to death. Patients for whom there was no evidence of death at the time of analysis were censored on the date that they were last known to have been alive. The Kaplan-Meier method was used to calculate the estimates.
Time frame: From randomisation to death, up to 3 years.
Time to Progression
Time to progression is defined as the time period from randomisation to objective tumour progression. Patients with no progression (by RECIST Version 1.1) were censored at the date of the last evaluable imaging. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates.
Time frame: From randomisation up to objective tumour progression, up to 3 years.
Time to Treatment Failure
Time to treatment failure was defined as the time from randomisation to objective tumour progression (by RECIST Version 1.1), death, global deterioration of health status requiring treatment discontinuation, or start of new anticancer treatment, whichever came first. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.The Kaplan-Meier method was used to calculate the estimates.
Time frame: From randomisation up to objective tumour progression, up to 3 years.
Time-matched Change From Baseline to Day 1 in QTcF (QT Interval Corrected by the Fridericia Formula) at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 obtained at time t minus baseline QTcF measurement at time t. Time-matched change from baseline to Day 1 in QTcF was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 1 are reported.
Time frame: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 of treatment Cycle 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.
Time-matched Change From Baseline in QTcF Interval (QT Interval Corrected by the Fridericia Formula) at the Time of Each Participant's Maximum Plasma Concentration of Nintedanib (BIBF 1120), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Time-Matched Change From Baseline in QTcF Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Time-Matched Change From Baseline in QTcF Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Average Time-matched Changes From Baseline in QTcF Interval Over 1 h to 12 h After Dosing on Days 1 and 15 of Treatment Cycle 1
Average time-matched in QTcF interval (QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula) changes over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.
Time frame: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.
Time-matched Changes From Baseline to Day 15 in QT Interval at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
QT interval is the electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 15 in QT at time t was defined as the QT measurement following administration of nintedanib on Day 15 obtained at time t minus baseline QT measurement at time t. 0 h is 5 min prior to dosing on Day 15. Time-matched change from baseline to Day 15 in QT was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 15 of Cycle 1are reported.
Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time-matched Changes From Baseline to Day 1 in QT Interval at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
QT interval is the electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 obtained at time t minus baseline QT measurement at time t. Time-matched change from baseline to Day 1 in QT was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 1 are reported.
Time frame: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.
Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration of Nintedanib (BIBF 1120), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.
Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Averaged Time-matched Changes From Baseline in QT Interval (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) Over 1 h to 12 h After Dosing on Days 1 and 15 of Treatment Cycle 1
Averaged time-matched QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) changes from baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120) to Day 1 (first drug dose nintedanib (BIBF 1120)) and to Day 15 (steady state) over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.
Time frame: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle.
Time-Matched Heart Rate (HR) Changes From Baseline to Day 15 at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib (BIBF 1120) at time t. Time-matched change from baseline to Day 15 in HR at time t was defined as the HR measurement following administration of nintedanib (BIBF 1120) on Day 15 obtained at time t minus baseline HR measurement at time t. 0 h is 5 min prior to dosing on Day 15. Time-matched change from baseline to Day 15 in HR was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib (BIBF 1120) on Day 15 of Cycle 1 are reported.
Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time-Matched Heart Rate (HR) Changes From Baseline to Day 1 at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib (BIBF 1120) at time t. Time-matched change from baseline to Day 1 in HR at time t was defined as the HR measurement following administration of nintedanib (BIBF 1120) on Day 1 obtained at time t minus baseline HR measurement at time t. Time-matched change from baseline to Day 1 in HR was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib (BIBF 1120) on Day 1 are reported.
Time frame: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.
Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Nintedanib (BIBF 1120) Plasma Concentration, Calculated Separately for Days 1 and 15 of Treatment Cycle 1
Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of treatment cycle 1. Continues in the description.
Averaged Time-Matched Heart Rate (HR) Change From Baseline Over 1 to 12 Hours, Calculated Separately for Days 1 and 15 of Treatment Cycle 1
Averaged time-matched heart rate changes from baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) to Day 1 (first drug dose nintedanib (BIBF 1120)) and to Day 15 (steady state) over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.
Time frame: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15.
Frequency of Patients With Maximum Time-Matched QTcF Interval Change From Baseline Categorized by Magnitude of Change, Calculated Separately for Days 1 and 15 of Treatment Cycle 1
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of patients with maximum time-matched change from baseline in the QTcF interval observed at each point in time, i.e., 9 time points on Day 1 and 10 timepoints on Day 15 is reported. 3 categories of individual QTcF increases from baseline to maximum value were defined: \<= 30 milliseconds (ms) \> 30 to 60 milliseconds (ms) \> 60 milliseconds (ms) Changes more than 60 ms in the QTcF interval represent notable changes. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Frequency of Patients With Maximum Time-Matched QT Interval (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) Change From Baseline Categorized by Magnitude of Change, Days 1 and 15
Number of patients with maximum time-matched change from baseline in the QT interval observed at each point in time, i.e., 9 time points on Day 1 and 10 timepoints on Day 15 is reported. 3 categories of individual QTcF increases from baseline to maximum value were defined: \<= 30 milliseconds (ms) \> 30 to 60 milliseconds (ms) \> 60 milliseconds (ms) Changes more than 60 ms in the QT interval represent notable changes. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF ≤450 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset (not present at any time pre-dose) of QTcF ≤450 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF >450 to 470 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset of QTcF \>450 to 470 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.
Number of Participants With New Onset of QTcF> 470 to 500 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset of QTcF\> 470 to 500 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.
Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF> 500 Milliseconds (ms) (Notable Prolongation), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset of QTcF\> 500 milliseconds (ms) (notable prolongation) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.
Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QT (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) > 500 ms (Notable Prolongation), Days 1 and 15 of Treatment Cycle 1
Number of participants with new onset of QT (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave)\> 500 milliseconds (ms) (notable prolongation) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.
Absolute Values at Baseline (Day -1) and Day 1 and Changes From Baseline to Day 1 at Each Point in Time in PR Interval
The PR interval is an electrocardiogram (ECG) interval and is the time from the onset of the P wave to the start of the QRS complex (combination of the Q wave, R wave and S wave). It reflects conduction through the atrioventricular node (AV) node. The normal PR interval is between 120 - 200 milliseconds (ms) (0.12-0.20s) in duration. Absolute values at baseline (Day-1 prior to the first dosing of nintedanib) and at Day 1 (first drug dose of nintedanib (BIBF 1120)) and changes from baseline to Day 1 at each point in time i.e., 10 time points from 0 to 12 in the PR interval are reported.
Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.
Absolute Values at Baseline (Day -1) and Day 15 and Changes From Baseline to Day 15 at Each Point in Time in PR Interval
The PR interval is an electrocardiogram (ECG) interval and is the time from the onset of the P wave to the start of the QRS complex (combination of the Q wave, R wave and S wave). It reflects conduction through the atrioventricular node (AV) node. The normal PR interval is between 120 - 200 milliseconds (ms) (0.12-0.20s) in duration. Absolute values at baseline (Day-1 prior to the first dosing of nintedanib (BIBF 1120) and at Day 15 (steady state) and changes from baseline to Day 15 at each point in time i.e., 10 time points from 0 to 12 in the PR interval are reported.
Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Absolute Values at Baseline (Day -1) and Day 1 and Changes From Baseline to Day 1 at Each Point in Time in QRS Interval
QRS interval is an electrocardiogram (ECG) interval and is the time interval from the onset to the end of the QRS complex (combination of the Q wave, R wave and S wave). The normal QRS duration is less than 120 milliseconds (ms). Absolute values and changes from baseline (Day-1 prior to the first dosing of nintedanib) to Day 1 (first drug dose of nintedanib (BIBF 1120)) at each point in time i.e., 10 time points from 0 to 12 in the QRS interval are reported.
Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.
Absolute Values at Baseline (Day -1) and Day 15 and Changes From Baseline to Day 15 at Each Point in Time in QRS Interval
QRS interval is an electrocardiogram (ECG) interval and is the time interval from the onset to the end of the QRS complex (combination of the Q wave, R wave and S wave). The normal QRS duration is less than 120 milliseconds (ms). Absolute values and changes from baseline (Day-1 prior to the first dosing of nintedanib) to Day 15 (steady state) at each point in time i.e., 10 time points from 0 to 12 in the QRS interval are reported.
Time frame: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Frequency of Patients by Clinical Electrocardiogram (ECG) Measurement Interpretation, Calculated Separately for Days 1 and 15 of Treatment Cycle 1
Based on the interpretation of the electrocardiogram (ECG) patients were classified in 3 categories: * Normal (a normal ECG reading would be a reading that includes the following normal findings: 1) normal general features; 2) no arrhythmia; 3) no conduction delays; 4) T-wave morphology of normal; and 5) normal U-wave morphology) on Day 1 or on Day 15) * Not normal and not normal at baseline (an abnormal ECG reading would be a reading that includes one or more of the following abnormal findings: 1) abnormal general features; 2) arrhythmia; 3) conduction delays; 4) T-wave morphology of flat, inverted or biphasic; and 5) abnormal U-wave morphology) on Day 1 or on Day 15) * Not normal and new onset of finding; Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
Time frame: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.
Frequency of Adverse Events Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0
The number of participants who experienced adverse events graded according to NCI CTCAE version 3.0, is reported below.The maximum grade of adverse event intensity for each type of treatment-related adverse event was recorded for each patient. Grade 1 - Mild AE Grade 2 - Moderate AE Grade 3 - Severe AE Grade 4 - Life-threatening or disabling AE Grade 5 - Death related to AE
Time frame: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.
Number of Participants With Adverse Events Leading to Dose Reduction
Number of participants who experienced Adverse Events which led to dose reduction of the trial medication is reported for each treatment arm.
Time frame: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.
Number of Participants With Adverse Events Leading to Discontinuation of Trial Drug
Number of participants with Adverse Events which lead to discontinuation of trial medication drug is reported for each treatment arm.
Time frame: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.
Number of Participants With Adverse Events Requiring or Prolonging Hospitalisation
Number of participants who experienced Adverse Events which required or prolonged hospitalisation of patients is reported for each treatment arm.
Time frame: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.
Duration of Hospital Stays Due to Adverse Events Requiring or Prolonging Hospitalisation
Duration of hospitalisation in days for each treatment arm is reported for those patients who experienced adverse events which required or prolonged hospitalisation (of the patients).
Time frame: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.
Frequency of Patients With Possible Clinically Significant Abnormal Lab Values
Number of patients with possible clinically significant abnormal lab values for the lab parameters alkaline phosphatase, activated partial thromboplastin time (APTT), creatinine, haemoglobin, prothrombin time (PT)-international normalized ratio (INR), potassium, lymphocytes, sodium, neutrophils, platelets, aspartate amino transferase (AST), alanine aminotransferase (ALT), bilirubin and white blood cell count is reported. Only lab values with CTCAE rule for possible clinical significance are displayed.
Time frame: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.
An open-label, 2:1 randomised, parallel-arm comparison of nintedanib versus sunitinib in patients with advanced renal cell cancer (RCC) who had not received prior systemic therapy.
| Milestone | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Started | 67 | 32 |
| Treated | 64 | 32 |
| Completed | 0 | 0 |
| Not completed | 67 | 32 |
| Withdrew: Progressive disease | 47 | 25 |
| Withdrew: Adverse event | 8 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Patient refusal to continue | 4 | 0 |
| Withdrew: Other than listed | 5 | 1 |
| Withdrew: Not treated | 3 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
Progression free survival rate at 9 months is the estimated probability of being alive and not having progressive disease at 9 months after randomisation. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria version 1.1 (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.
| Probability | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Probability Rates of Progression-free Survival at 9 Months | 0.431 (0.306 to 0.550) | 0.452 (0.274 to 0.614) |
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 15 in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 15 obtained at time t minus baseline QTcF measurement at time t. 0 h is 5 min prior to dosing on Day 15. Time-matched change from baseline to Day 15 in QTcF was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h,1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 15 of are reported.
| milliseconds (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched change from baseline to Day 15 at -5 minutes (min) | 2.6 (-0.7 to 5.9) |
| Time-matched change from baseline to Day 15 at 1 hour (h) | 0.4 (-2.8 to 3.7) |
| Time-matched change from baseline to Day 15 at 2 h | -1.7 (-4.9 to 1.6) |
| Time-matched change from baseline to Day 15 at 3 h | -0.5 (-3.8 to 2.8) |
| Time-matched change from baseline to Day 15 at 4 h | -0.5 (-3.8 to 2.8) |
| Time-matched change from baseline to Day 15 at 5 h | 0.3 (-3.0 to 3.6) |
| Time-matched change from baseline to Day 15 at 6 h | 2.2 (-1.1 to 5.5) |
| Time-matched change from baseline to Day 15 at 7 h | 3.1 (-0.2 to 6.4) |
| Time-matched change from baseline to Day 15 at 10 h | 0.1 (-3.2 to 3.4) |
| Time-matched change from baseline to Day 15 at 12 h | 1.6 (-1.7 to 4.9) |
Progression free survival (PFS) from randomisation to the occurrence of disease progression (by RECIST Version 1.1) or death, whichever occurred first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates.
| Months | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Progression Free Survival (PFS) | 8.44 (5.59 to 11.10) | 8.38 (5.59 to 13.86) |
Objective response was defined as complete response (CR, the disappearance of all target and non-target lesions and no new lesions) or partial response (PR, at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum of the longest diameters and no new lesions) as determined by RECIST Version 1.1. Numbers of participants with objective response are reported. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.
| Participants | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Complete Response | 0 | 1 |
| Partial response | 14 | 11 |
Duration (months) of objective response was measured from the time of first objective response to the time of disease progression (by RECIST Version 1.1) or death, whichever occurred first. Objective response was defined as complete response (CR, the disappearance of all target and non-target lesions and no new lesions) or partial response (PR, at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum of the longest diameters and no new lesions) as determined by RECIST Version 1.1. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates.
| Months | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Duration of Objective Response | 19.42 (8.31 to NA) | 11.66 (7.06 to 28.45) |
Overall survival was calculated as the time (months) from randomisation to death. Patients for whom there was no evidence of death at the time of analysis were censored on the date that they were last known to have been alive. The Kaplan-Meier method was used to calculate the estimates.
| Months | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Overall Survival | 20.37 (13.86 to 29.01) | 21.22 (11.01 to 31.74) |
Time to progression is defined as the time period from randomisation to objective tumour progression. Patients with no progression (by RECIST Version 1.1) were censored at the date of the last evaluable imaging. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates.
| Months | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Time to Progression | 8.48 (7.56 to 11.20) | 8.54 (5.68 to 13.90) |
Time to treatment failure was defined as the time from randomisation to objective tumour progression (by RECIST Version 1.1), death, global deterioration of health status requiring treatment discontinuation, or start of new anticancer treatment, whichever came first. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.The Kaplan-Meier method was used to calculate the estimates.
| Month | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Time to Treatment Failure | 8.44 (5.62 to 10.97) | 8.36 (5.55 to 13.86) |
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 obtained at time t minus baseline QTcF measurement at time t. Time-matched change from baseline to Day 1 in QTcF was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 1 are reported.
| milliseconds (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched change from baseline to Day 1 at 1 hour (h) | -1.6 (-4.4 to 1.2) |
| Time-matched change from baseline to Day 1 at 2 h | -3.1 (-6.0 to -0.3) |
| Time-matched change from baseline to Day 1 at 3 h | -2.6 (-5.5 to 0.2) |
| Time-matched change from baseline to Day 1 at 4 h | -2.6 (-5.4 to 0.3) |
| Time-matched change from baseline to Day 1 at 5 h | -1.4 (-4.3 to 1.4) |
| Time-matched change from baseline to Day 1 at 6 h | -2.0 (-4.8 to 0.9) |
| Time-matched change from baseline to Day 1 at 7 h | -1.5 (-4.4 to 1.3) |
| Time-matched change from baseline to Day 1 at 10 h | -3.6 (-6.4 to -0.7) |
| Time-matched change from baseline to Day 1 at 12 h | -2.2 (-5.0 to 0.7) |
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| milliseconds (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched change from baseline in QTcF interval at maximum BIBF 1120 concentration on Day 1 | -2.8 (-5.0 to -0.6) |
| Time-matched change from baseline in QTcF interval at maximum BIBF 1120 concentration on Day 15 | -3.2 (-5.9 to -0.4) |
Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| milliseconds (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched change from baseline in QTcF interval at maximum BIBF 1202 concentration on Day 1 | -2.5 (-4.6 to -0.5) |
| Time-matched change from baseline in QTcF interval at maximum BIBF 1202 concentration on Day 15 | -1.1 (-3.8 to 1.6) |
Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline values were taken at exactly the same time points as on Day 15.
| milliseconds (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched change in QTcF from baseline at maximum BIBF 1202-glucuronide concentration on Day 1 | -2.4 (-4.9 to 0.0) |
| Time-matched change in QTcF from baseline at maximum BIBF 1202-glucuronide concentration on Day 15 | -1.5 (-4.2 to 1.2) |
Average time-matched in QTcF interval (QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula) changes over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.
| milliseconds (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Averaged time-matched changes from baseline in QTcF interval over 1 h to 12 h after dosing on Day 1 | -2.2 (-3.5 to -0.8) |
| Averaged time-matched changes from baseline in QTcF interval over 1 h to 12 h after dosing on Day 15 | 0.5 (-1.4 to 2.3) |
QT interval is the electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 15 in QT at time t was defined as the QT measurement following administration of nintedanib on Day 15 obtained at time t minus baseline QT measurement at time t. 0 h is 5 min prior to dosing on Day 15. Time-matched change from baseline to Day 15 in QT was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 15 of Cycle 1are reported.
| milliseconds (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched QT interval change from baseline to Day 15 at -5 minutes (min) | 1.0 (-3.6 to 5.6) |
| Time-matched QT interval change from baseline to Day 15 at 1 hour (h) | 0.5 (-4.1 to 5.1) |
| Time-matched QT interval change from baseline to Day 15 at 2 h | 1.6 (-3.0 to 6.2) |
| Time-matched QT interval change from baseline to Day 15 at 3 h | 4.4 (-0.2 to 9.0) |
| Time-matched QT interval change from baseline to Day 15 at 4 h | 4.7 (0.0 to 9.3) |
| Time-matched QT interval change from baseline to Day 15 at 5 h | 5.1 (0.5 to 9.7) |
| Time-matched QT interval change from baseline to Day 15 at 6 h | 7.7 (3.1 to 12.3) |
| Time-matched QT interval change from baseline to Day 15 at 7 h | 7.1 (2.5 to 11.7) |
| Time-matched QT interval change from baseline to Day 15 at 10 h | 3.4 (-1.2 to 8.0) |
| Time-matched QT interval change from baseline to Day 15 at 12 h | 4.2 (-0.4 to 8.8) |
QT interval is the electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 obtained at time t minus baseline QT measurement at time t. Time-matched change from baseline to Day 1 in QT was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 1 are reported.
| millisecond (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched QT interval change from baseline to Day 1 at 1 hour (h) | -2.0 (-6.3 to 2.3) |
| Time-matched QT interval change from baseline to Day 1 at 2 h | 1.6 (-2.8 to 5.9) |
| Time-matched QT interval change from baseline to Day 1 at 3 h | 3.5 (-0.8 to 7.8) |
| Time-matched QT interval change from baseline to Day 1 at 4 h | 1.4 (-2.9 to 5.7) |
| Time-matched QT interval change from baseline to Day 1 at 5 h | 1.4 (-2.9 to 5.7) |
| Time-matched QT interval change from baseline to Day 1 at 6 h | 1.8 (-2.6 to 6.1) |
| Time-matched QT interval change from baseline to Day 1 at 7 h | 0.7 (-3.6 to 5.0) |
| Time-matched QT interval change from baseline to Day 1 at 10 h | -1.7 (-6.0 to 2.7) |
| Time-matched QT interval change from baseline to Day 1 at 12 h | -2.2 (-6.5 to 2.2) |
QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.
| millisecond (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched change from baseline in QT interval at maximum BIBF 1120 concentration on Day 1 | 0.9 (-2.3 to 4.0) |
| Time-matched change from baseline in QT interval at maximum BIBF 1120 concentration on Day 15 | -0.4 (-5.0 to 4.1) |
QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| millisecond (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched change from baseline in QT interval at maximum BIBF 1202 concentration on Day 1 | 1.2 (-1.9 to 4.3) |
| Time-matched change from baseline in QT interval at maximum BIBF 1202 concentration on Day 15 | 1.8 (-2.7 to 6.3) |
QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| millisecond (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched change from baseline in QT at maximum BIBF 1202-glucuronide concentration on Day 1 | -0.4 (-4.0 to 3.1) |
| Time-matched change from baseline in QT at maximum BIBF 1202-glucuronide concentration on Day 15 | 1.3 (-3.2 to 5.9) |
Averaged time-matched QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) changes from baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120) to Day 1 (first drug dose nintedanib (BIBF 1120)) and to Day 15 (steady state) over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.
| millisecond (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Averaged time-matched changes from baseline in QT interval over 1 h to 12 h after dosing on Day 1 | 0.9 (-1.3 to 3.0) |
| Averaged time-matched changes from baseline in QT interval over 1 h to 12 h after dosing on Day 15 | 4.2 (0.6 to 7.7) |
Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib (BIBF 1120) at time t. Time-matched change from baseline to Day 15 in HR at time t was defined as the HR measurement following administration of nintedanib (BIBF 1120) on Day 15 obtained at time t minus baseline HR measurement at time t. 0 h is 5 min prior to dosing on Day 15. Time-matched change from baseline to Day 15 in HR was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib (BIBF 1120) on Day 15 of Cycle 1 are reported.
| beats per minute (bpm) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched heart rate (HR) change from baseline to Day 15 at -5 minutes (min) | 0.9 (-1.2 to 3.0) |
| Time-matched heart rate (HR) change from baseline to Day 15 at 1 h | -0.3 (-2.4 to 1.9) |
| Time-matched heart rate (HR) change from baseline to Day 15 at 2 h | -2.0 (-4.2 to 0.1) |
| Time-matched heart rate (HR) change from baseline to Day 15 at 3 h | -3.3 (-5.4 to -1.2) |
| Time-matched heart rate (HR) change from baseline to Day 15 at 4 h | -3.4 (-5.5 to -1.3) |
| Time-matched heart rate (HR) change from baseline to Day 15 at 5 h | -3.1 (-5.2 to -1.0) |
| Time-matched heart rate (HR) change from baseline to Day 15 at 6 h | -3.8 (-5.9 to -1.7) |
| Time-matched heart rate (HR) change from baseline to Day 15 at 7 h | -2.8 (-4.9 to -0.7) |
| Time-matched heart rate (HR) change from baseline to Day 15 at 10 h | -2.4 (-4.5 to -0.5) |
| Time-matched heart rate (HR) change from baseline to Day 15 at 12 h | -1.6 (-3.8 to 0.5) |
Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib (BIBF 1120) at time t. Time-matched change from baseline to Day 1 in HR at time t was defined as the HR measurement following administration of nintedanib (BIBF 1120) on Day 1 obtained at time t minus baseline HR measurement at time t. Time-matched change from baseline to Day 1 in HR was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib (BIBF 1120) on Day 1 are reported.
| beats per minute (bpm) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched heart rate (HR) change from baseline to Day 1 at 1 hour (h) | -0.0 (-1.9 to 1.8) |
| Time-matched heart rate (HR) change from baseline to Day 1 at 2 h | -2.9 (-4.7 to -1.0) |
| Time-matched heart rate (HR) change from baseline to Day 1 at 3 h | -3.8 (-5.7 to -2.0) |
| Time-matched heart rate (HR) change from baseline to Day 1 at 4 h | -2.5 (-4.3 to -0.6) |
| Time-matched heart rate (HR) change from baseline to Day 1 at 5 h | -1.8 (-3.7 to 0.0) |
| Time-matched heart rate (HR) change from baseline to Day 1 at 6 h | -2.2 (-4.1 to -0.4) |
| Time-matched heart rate (HR) change from baseline to Day 1 at 7 h | -1.4 (-3.3 to 0.4) |
| Time-matched heart rate (HR) change from baseline to Day 1 at 10 h | -1.3 (-3.2 to 0.6) |
| Time-matched heart rate (HR) change from baseline to Day 1 at 12 h | 0.0 (-1.8 to 1.9) |
Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| beats per minute (bpm) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched change from baseline in HR at maximum BIBF 1120 concentration on Day 1 | -2.0 (-3.4 to -0.7) |
| Time-matched change from baseline in HR at maximum BIBF 1120 concentration on Day 15 | -2.1 (-4.3 to 0.1) |
Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| beats per minute (bpm) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched change from baseline in HR at maximum BIBF 1202 concentration on Day 1 | -2.3 (-3.8 to -0.8) |
| Time-matched change from baseline in HR at maximum BIBF 1202 concentration on Day 15 | -2.0 (-4.2 to 0.1) |
Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t. For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.
| beats per minute (bpm) | Nintedanib (BIBF 1120) |
|---|---|
| Time-matched change from baseline in HR at maximum BIBF 1202-glucuronide concentration on Day 1 | -1.2 (-2.6 to 0.3) |
| Time-matched change from baseline in HR at maximum BIBF 1202-glucuronide concentration on Day 15 | -1.6 (-3.6 to 0.4) |
Averaged time-matched heart rate changes from baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) to Day 1 (first drug dose nintedanib (BIBF 1120)) and to Day 15 (steady state) over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15.
| beats per minute (bpm) | Nintedanib (BIBF 1120) |
|---|---|
| Averaged time-matched HR change from baseline over 1 to 12 hours on Day 1 | -1.9 (-2.8 to -1.1) |
| Averaged time-matched HR change from baseline over 1 to 12 hours on Day 15 | -2.5 (-4.0 to -0.9) |
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of patients with maximum time-matched change from baseline in the QTcF interval observed at each point in time, i.e., 9 time points on Day 1 and 10 timepoints on Day 15 is reported. 3 categories of individual QTcF increases from baseline to maximum value were defined: \<= 30 milliseconds (ms) \> 30 to 60 milliseconds (ms) \> 60 milliseconds (ms) Changes more than 60 ms in the QTcF interval represent notable changes. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| Participants | Nintedanib (BIBF 1120) |
|---|---|
| Frequency of patients with maximum time-matched QTcF change from baseline on Day 1, 1-12 hours (h) — <= 30 milliseconds (ms) | 64 |
| Frequency of patients with maximum time-matched QTcF change from baseline on Day 1, 1-12 hours (h) — > 30 to 60 milliseconds (ms) | 0 |
| Frequency of patients with maximum time-matched QTcF change from baseline on Day 1, 1-12 hours (h) — > 60 milliseconds (ms) | 0 |
| Frequency of patients with maximum time-matched QTcF change from baseline on Day 15, -0:05-12 h — <= 30 milliseconds (ms) | 57 |
| Frequency of patients with maximum time-matched QTcF change from baseline on Day 15, -0:05-12 h — > 30 to 60 milliseconds (ms) | 6 |
| Frequency of patients with maximum time-matched QTcF change from baseline on Day 15, -0:05-12 h — > 60 milliseconds (ms) | 0 |
Number of patients with maximum time-matched change from baseline in the QT interval observed at each point in time, i.e., 9 time points on Day 1 and 10 timepoints on Day 15 is reported. 3 categories of individual QTcF increases from baseline to maximum value were defined: \<= 30 milliseconds (ms) \> 30 to 60 milliseconds (ms) \> 60 milliseconds (ms) Changes more than 60 ms in the QT interval represent notable changes. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| Participants | Nintedanib (BIBF 1120) |
|---|---|
| Frequency of patients with maximum time-matched QTcF change from baseline on Day 1, 1-12 hour (h) — <= 60 milliseconds (ms) | 64 |
| Frequency of patients with maximum time-matched QTcF change from baseline on Day 1, 1-12 hour (h) — > 60 milliseconds (ms) | 0 |
| Frequency of patients with maximum time-matched QTcF change from baseline on Day 15, -0:05-12 h — <= 60 milliseconds (ms) | 62 |
| Frequency of patients with maximum time-matched QTcF change from baseline on Day 15, -0:05-12 h — > 60 milliseconds (ms) | 1 |
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset (not present at any time pre-dose) of QTcF ≤450 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| Participants | Nintedanib (BIBF 1120) |
|---|---|
| Number of participants with new onset of QTcF ≤450 (ms) on Day 1 | 3 |
| Number of participants with new onset of QTcF ≤450 (ms) on Day 15 | 2 |
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset of QTcF \>450 to 470 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| Participants | Nintedanib (BIBF 1120) |
|---|---|
| Number of participants with new onset of QTcF >450 to 470 ms on Day 1 | 1 |
| Number of participants with new onset of QTcF >450 to 470 ms on Day 15 | 1 |
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset of QTcF\> 470 to 500 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| Participants | Nintedanib (BIBF 1120) |
|---|---|
| Number of participants with new onset of QTcF> 470 to 500 ms on Day 1 | 0 |
| Number of participants with new onset of QTcF> 470 to 500 ms on Day 15 | 1 |
QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Number of participants with new onset of QTcF\> 500 milliseconds (ms) (notable prolongation) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| Participants | Nintedanib (BIBF 1120) |
|---|---|
| Number of participants with new onset of QTcF> 500 (ms) on Day 1, 1-12 hour (h) | 0 |
| Number of participants with new onset of QTcF> 500 (ms) (notable prolongation) on Day 15, -0:05-12 h | 0 |
Number of participants with new onset of QT (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave)\> 500 milliseconds (ms) (notable prolongation) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| Participants | Nintedanib (BIBF 1120) |
|---|---|
| Number of participants with new onset of QT> 500 (ms) on Day 1, 1-12 hour (h) | 0 |
| Number of participants with new onset of QT> 500 (ms) on Day 15, -0:05-12 h | 0 |
The PR interval is an electrocardiogram (ECG) interval and is the time from the onset of the P wave to the start of the QRS complex (combination of the Q wave, R wave and S wave). It reflects conduction through the atrioventricular node (AV) node. The normal PR interval is between 120 - 200 milliseconds (ms) (0.12-0.20s) in duration. Absolute values at baseline (Day-1 prior to the first dosing of nintedanib) and at Day 1 (first drug dose of nintedanib (BIBF 1120)) and changes from baseline to Day 1 at each point in time i.e., 10 time points from 0 to 12 in the PR interval are reported.
| milliseconds (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Absolute value in PR interval on Day -1 at -5 minutes (min) | 164.7 ± 23.8 |
| Absolute value in PR interval on Day -1 at 1 hour (h) | 165.7 ± 24.9 |
| Absolute value in PR interval on Day -1 at 2 h | 166.8 ± 24.9 |
| Absolute value in PR interval on Day -1 at 3 h | 166.6 ± 24.0 |
| Absolute value in PR interval on Day -1 at 4 h | 168.1 ± 26.9 |
| Absolute value in PR interval on Day -1 at 5 h | 167.2 ± 26.3 |
| Absolute value in PR interval on Day -1 at 6 h | 168.1 ± 26.4 |
| Absolute value in PR interval on Day -1 at 7 h | 168.9 ± 27.5 |
| Absolute value in PR interval on Day -1 at 10 h | 168.0 ± 26.7 |
| Absolute value in PR interval on Day -1 at 12 h | 170.0 ± 29.4 |
| Absolute value in PR interval on Day 1 at -5 min | 165.7 ± 25.6 |
| Absolute value in PR interval on Day 1 at 1 h | 167.4 ± 28.2 |
| Absolute value in PR interval on Day 1 at 2 h | 169.4 ± 28.2 |
| Absolute value in PR interval on Day 1 at 3 h | 170.0 ± 27.3 |
| Absolute value in PR interval on Day 1 at 4 h | 170.0 ± 28.2 |
| Absolute value in PR interval on Day 1 at 5 h | 169.4 ± 27.5 |
| Absolute value in PR interval on Day 1 at 6 h | 170.8 ± 27.9 |
| Absolute value in PR interval on Day 1 at 7 h | 169.9 ± 27.0 |
| Absolute value n PR interval on Day 1 at 10 h | 169.8 ± 26.3 |
| Absolute value in PR interval on Day 1 at 12 h | 171.3 ± 28.7 |
| Time-matched change from Day -1 to Day 1 in PR interval at -5 min | 0.7 ± 7.6 |
| Time-matched change from Day -1 to Day 1 in PR interval at 1 h | 1.7 ± 11.6 |
| Time-matched change from Day -1 to Day 1 in PR interval at 2 h | 2.6 ± 10.3 |
| Time-matched change from Day -1 to Day 1 in PR interval at 3 h | 3.4 ± 9.1 |
| Time-matched change from Day -1 to Day 1 in PR interval at 4 h | 2.2 ± 9.1 |
| Time-matched change from Day -1 to Day 1 in PR interval at 5 h | 2.8 ± 10.7 |
| Time-matched change from Day -1 to Day 1 in PR interval at 6 h | 3.3 ± 9.8 |
| Time-matched change from Day -1 to Day 1 in PR interval at 7 h | 1.6 ± 9.3 |
| Time-matched change from Day -1 to Day 1 in PR interval at 10 h | 1.8 ± 8.6 |
| Time-matched change from Day -1 to Day 1 in PR interval at 12 h | 0.7 ± 9.4 |
The PR interval is an electrocardiogram (ECG) interval and is the time from the onset of the P wave to the start of the QRS complex (combination of the Q wave, R wave and S wave). It reflects conduction through the atrioventricular node (AV) node. The normal PR interval is between 120 - 200 milliseconds (ms) (0.12-0.20s) in duration. Absolute values at baseline (Day-1 prior to the first dosing of nintedanib (BIBF 1120) and at Day 15 (steady state) and changes from baseline to Day 15 at each point in time i.e., 10 time points from 0 to 12 in the PR interval are reported.
| milliseconds (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Absolute value in PR interval on Day -1 at -5 minutes (min) | 164.7 ± 24.0 |
| Absolute value in PR interval on Day -1 at 1 h | 165.7 ± 25.1 |
| Absolute value in PR interval on Day -1 at 2 h | 166.8 ± 25.1 |
| Absolute value in PR interval on Day -1 at 3 h | 166.5 ± 24.2 |
| Absolute value in PR interval on Day -1 at 4 h | 168.0 ± 27.2 |
| Absolute value in PR interval on Day -1 at 5 h | 167.2 ± 26.5 |
| Absolute value in PR interval on Day -1 at 6 h | 168.3 ± 26.6 |
| Absolute value in PR interval on Day -1 at 7 h | 168.9 ± 27.7 |
| Absolute value in PR interval on Day -1 at 10 h | 168.1 ± 26.9 |
| Absolute value in PR interval on Day -1 at 12 h | 170.1 ± 29.7 |
| Absolute value in PR interval on Day 15 at -5 min | 164.5 ± 24.4 |
| Absolute value in PR interval on Day 15 at 1 h | 166.1 ± 25.3 |
| Absolute value in PR interval on Day 15 at 2 h | 166.8 ± 26.2 |
| Absolute value in PR interval on Day 15 at 3 h | 167.4 ± 25.3 |
| Absolute value in PR interval on Day 15 at 4 h | 168.7 ± 27.4 |
| Absolute value in PR interval on Day 15 at 5 h | 167.7 ± 27.8 |
| Absolute value in PR interval on Day 15at 6 h | 169.3 ± 26.7 |
| Absolute value in PR interval on Day 15 at 7 h | 169.0 ± 27.9 |
| Absolute value in PR interval on Day 15 at 10 h | 169.1 ± 27.9 |
| Absolute value in PR interval on Day 15 at 12:00 h:min | 168.8 ± 27.9 |
| Time-matched change from Day -1 to Day 15 in PR interval at -5 min | -0.1 ± 10.6 |
| Time-matched change from Day -1 to Day 15 in PR interval at 1 h | 0.5 ± 12.5 |
| Time-matched change from Day -1 to Day 15 in PR interval at 2 h | -0.0 ± 12.7 |
| Time-matched change from Day -1 to Day 15 in PR interval at 3 h | 0.9 ± 14.6 |
| Time matched - change from Day -1 to Day 15 in PR interval at 4 h | 0.9 ± 12.2 |
| Time-matched change from Day -1 to Day 15 in PR interval at 5 h | 0.9 ± 13.7 |
| Time-matched change from Day -1 to Day 15 in PR interval at 6 h | 1.3 ± 11.8 |
| Time-matched change from Day -1 to Day 15 in PR interval at 7 h | 0.6 ± 13.2 |
| Time-matched change from Day -1 to Day 15 in PR interval at 10 h | 1.2 ± 11.2 |
| Time-matched change from Day -1 to Day 15 in PR interval at 12 h | -1.5 ± 12.5 |
QRS interval is an electrocardiogram (ECG) interval and is the time interval from the onset to the end of the QRS complex (combination of the Q wave, R wave and S wave). The normal QRS duration is less than 120 milliseconds (ms). Absolute values and changes from baseline (Day-1 prior to the first dosing of nintedanib) to Day 1 (first drug dose of nintedanib (BIBF 1120)) at each point in time i.e., 10 time points from 0 to 12 in the QRS interval are reported.
| milliseconds (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Absolute value in QRS interval on Day -1 at -5 minutes (min) | 92.4 ± 11.8 |
| Absolute value in QRS interval on Day -1 at 1 h | 93.7 ± 11.0 |
| Absolute value in QRS interval on Day -1 at 2 h | 93.2 ± 10.5 |
| Absolute value in QRS interval on Day -1 at 3 h | 93.6 ± 10.8 |
| Absolute value in QRS interval on Day -1 at 4 h | 92.7 ± 9.8 |
| Absolute value in QRS interval on Day -1 at 5 h | 92.6 ± 11.0 |
| Absolute value in QRS interval on Day -1 at 6 h | 92.5 ± 10.3 |
| Absolute value in QRS interval on Day -1 at 7 h | 93.0 ± 10.6 |
| Absolute value in QRS interval on Day -1 at 10 h | 92.8 ± 11.7 |
| Absolute value in QRS interval on Day -1, 12 h | 92.5 ± 10.4 |
| Absolute value in QRS interval on Day 1 at -5 min | 92.6 ± 10.1 |
| Absolute value in QRS interval on Day 1 at 1 h | 93.2 ± 11.0 |
| Absolute value in QRS interval on Day 1 at 2 h | 93.0 ± 10.4 |
| Absolute value in QRS interval on Day 1 at 3 h | 93.3 ± 10.3 |
| Absolute value in QRS interval on Day 1 at 4 h | 93.5 ± 11.1 |
| Absolute value in QRS interval on Day 1 at 5 h | 93.4 ± 11.5 |
| Absolute value in QRS interval on Day 1 at 6 h | 93.4 ± 10.7 |
| Absolute value in QRS interval on Day 1 at 7 h | 93.2 ± 11.3 |
| Absolute value in QRS interval on Day 1 at 10 h | 92.3 ± 10.6 |
| Absolute value in QRS interval on Day 1 at 12 h | 92.8 ± 10.9 |
| Time-matched change from Day -1 to Day 1 in QRS interval at -5 min | 0.7 ± 5.1 |
| Time-matched change from Day -1 to Day 1 in QRS interval at 1 h | -0.5 ± 5.2 |
| Time-matched change from Day -1 to Day 1 in QRS interval 2 h | -0.2 ± 4.4 |
| Time-matched change from Day -1 to Day 1 in QRS interval at 3h | -0.3 ± 4.4 |
| Time-matched change from Day -1 to day 1 in QRS interval at 4 h | 0.2 ± 4.7 |
| Time-matched change from Day -1 to Day 1 in QRS interval at 5 h | 0.2 ± 5.4 |
| Time-matched change from Day -1 to Day 1 in QRS interval at 6 h | 0.3 ± 5.6 |
| Time-matched change from Day -1 to Day 1 in QRS interval at 7 h | -0.2 ± 4.7 |
| Time-matched change from Day -1 to Day 1 in QRS interval at 10 h | -0.5 ± 4.9 |
| Time-matched change from Day -1 to Day 1 in QRS interval at 12 h | 0.3 ± 4.9 |
QRS interval is an electrocardiogram (ECG) interval and is the time interval from the onset to the end of the QRS complex (combination of the Q wave, R wave and S wave). The normal QRS duration is less than 120 milliseconds (ms). Absolute values and changes from baseline (Day-1 prior to the first dosing of nintedanib) to Day 15 (steady state) at each point in time i.e., 10 time points from 0 to 12 in the QRS interval are reported.
| milliseconds (ms) | Nintedanib (BIBF 1120) |
|---|---|
| Absolute value in QRS interval on Day -1 at -5 minutes (min) | 92.5 ± 11.8 |
| Absolute value in QRS interval on Day -1 at 1 hour (h) | 93.8 ± 11.1 |
| Absolute value in QRS interval on Day -1 at 2 h | 93.3 ± 10.6 |
| Absolute value in QRS interval on Day -1 at 3 h | 93.6 ± 10.9 |
| Absolute value in QRS interval on Day -1 at 4 h | 92.7 ± 9.9 |
| Absolute value in QRS interval on Day -1 at 5 h | 92.7 ± 11.0 |
| Absolute value in QRS interval on Day -1 at 6 h | 92.7 ± 10.3 |
| Absolute value in QRS interval on Day -1 at 7 h | 93.1 ± 10.6 |
| Absolute value in QRS interval on Day -1 at 10 h | 92.8 ± 11.8 |
| Absolute value in QRS interval on Day -1 at 12 h | 92.6 ± 10.4 |
| Absolute value in QRS interval on Day 15 at -5 min | 93.3 ± 11.0 |
| Absolute value Day 15, 1 h | 93.9 ± 10.3 |
| Absolute value in QRS interval on Day 15 at 2 h | 93.0 ± 11.5 |
| Absolute value in QRS interval on Day 15 at 3 h | 92.9 ± 11.1 |
| Absolute value in QRS interval on Day 15 at 4 h | 92.6 ± 11.2 |
| Absolute value in QRS interval on Day 15 at 5 h | 93.6 ± 10.9 |
| Absolute value in QRS interval on Day 15 at 6 h | 93.1 ± 11.1 |
| Absolute value in QRS interval on Day 15 at 7 h | 93.1 ± 11.3 |
| Absolute value in QRS interval on Day 15 at 10 h | 92.8 ± 10.7 |
| Absolute value in QRS interval on Day 15 at 12 h | 93.7 ± 11.5 |
| Time-matched change from Day -1 to Day 15 in QRS interval at -5 min | 0.8 ± 5.4 |
| Time-matched change from Day -1 to Day 15 in QRS interval at 1 h | 0.0 ± 5.1 |
| Time-matched change from Day -1 to Day 15 in QRS interval at 2 h | -0.3 ± 5.3 |
| Time-matched change from Day -1 to Day 15 in QRS interval at 3 h | -0.8 ± 5.7 |
| Time-matched change from Day -1 to Day 15 in QRS interval at 4 h | -0.6 ± 5.4 |
| Time-matched change from Day -1 to Day 15 in QRS interval at 5 h | 0.5 ± 7.3 |
| Time-matched change from Day -1 to Day 15 in QRS interval at 6 h | -0.1 ± 5.3 |
| Time-matched change from Day -1 to Day 15 in QRS interval at 7 h | -0.4 ± 5.3 |
| Time-matched change from Day -1 to Day 15 in QRS interval at 10 h | 0.1 ± 5.1 |
| Time-matched change from Day -1 to Day 15 in QRS interval at 12 h | 1.0 ± 4.7 |
Based on the interpretation of the electrocardiogram (ECG) patients were classified in 3 categories: * Normal (a normal ECG reading would be a reading that includes the following normal findings: 1) normal general features; 2) no arrhythmia; 3) no conduction delays; 4) T-wave morphology of normal; and 5) normal U-wave morphology) on Day 1 or on Day 15) * Not normal and not normal at baseline (an abnormal ECG reading would be a reading that includes one or more of the following abnormal findings: 1) abnormal general features; 2) arrhythmia; 3) conduction delays; 4) T-wave morphology of flat, inverted or biphasic; and 5) abnormal U-wave morphology) on Day 1 or on Day 15) * Not normal and new onset of finding; Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15.
| Participants | Nintedanib (BIBF 1120) |
|---|---|
| ECG interpretation on Day 1 — Normal | 39 |
| ECG interpretation on Day 1 — Not normal and not normal at baseline | 24 |
| ECG interpretation on Day 1 — Not normal and new onset of finding | 1 |
| ECG interpretation on Day 15 — Normal | 37 |
| ECG interpretation on Day 15 — Not normal and not normal at baseline | 25 |
| ECG interpretation on Day 15 — Not normal and new onset of finding | 1 |
The number of participants who experienced adverse events graded according to NCI CTCAE version 3.0, is reported below.The maximum grade of adverse event intensity for each type of treatment-related adverse event was recorded for each patient. Grade 1 - Mild AE Grade 2 - Moderate AE Grade 3 - Severe AE Grade 4 - Life-threatening or disabling AE Grade 5 - Death related to AE
| Participants | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Grade 1 | 11 | 5 |
| Grade 2 | 16 | 6 |
| Grade 3 | 14 | 16 |
| Grade 4 | 10 | 2 |
| Grade 5 | 7 | 1 |
Number of participants who experienced Adverse Events which led to dose reduction of the trial medication is reported for each treatment arm.
| Participants | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Number of Participants With Adverse Events Leading to Dose Reduction | 16 | 8 |
Number of participants with Adverse Events which lead to discontinuation of trial medication drug is reported for each treatment arm.
| Participants | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Number of Participants With Adverse Events Leading to Discontinuation of Trial Drug | 11 | 5 |
Number of participants who experienced Adverse Events which required or prolonged hospitalisation of patients is reported for each treatment arm.
| Participants | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Number of Participants With Adverse Events Requiring or Prolonging Hospitalisation | 15 | 10 |
Duration of hospitalisation in days for each treatment arm is reported for those patients who experienced adverse events which required or prolonged hospitalisation (of the patients).
| days | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Duration of Hospital Stays Due to Adverse Events Requiring or Prolonging Hospitalisation | 11.40 ± 8.56 | 13.10 ± 8.32 |
Number of patients with possible clinically significant abnormal lab values for the lab parameters alkaline phosphatase, activated partial thromboplastin time (APTT), creatinine, haemoglobin, prothrombin time (PT)-international normalized ratio (INR), potassium, lymphocytes, sodium, neutrophils, platelets, aspartate amino transferase (AST), alanine aminotransferase (ALT), bilirubin and white blood cell count is reported. Only lab values with CTCAE rule for possible clinical significance are displayed.
| Participants | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Alkaline phosphatase | 2 | 3 |
| APTT (Activated partial thrombopl. time) | 7 | 0 |
| Creatinine | 4 | 5 |
| Haemoglobin | 6 | 6 |
| Prothrombin time (PT)-international normalized ratio (INR) | 5 | 0 |
| Potassium | 14 | 4 |
| Lymphocytes | 8 | 11 |
| Sodium | 14 | 3 |
| Neutrophils | 3 | 9 |
| Platelets | 2 | 3 |
| Aspartate amino Transferase (AST) | 10 | 1 |
| Alanine aminotransferase (ALT) | 14 | 3 |
| Bilirubin, total | 4 | 3 |
| White blood cell count | 0 | 7 |
Collected over From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nintedanib (BIBF 1120) | 50/64 (78.1%) | 20/64 (31.3%) | 55/64 (85.9%) |
| Sunitinib | 25/32 (78.1%) | 11/32 (34.4%) | 27/32 (84.4%) |
| Event | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 7/64 | 0/32 |
| NauseaGastrointestinal disorders | 0/64 | 3/32 |
| Abdominal painGastrointestinal disorders | 0/64 | 2/32 |
| Myocardial infarctionCardiac disorders | 1/64 | 1/32 |
| Abdominal pain upperGastrointestinal disorders | 0/64 | 1/32 |
| AscitesGastrointestinal disorders | 0/64 | 1/32 |
| DiarrhoeaGastrointestinal disorders | 0/64 | 1/32 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/64 | 1/32 |
| VomitingGastrointestinal disorders | 0/64 | 1/32 |
| Disease progressionGeneral disorders | 0/64 | 1/32 |
| Event | Nintedanib (BIBF 1120) | Sunitinib |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 40/64 | 15/32 |
| NauseaGastrointestinal disorders | 25/64 | 8/32 |
| StomatitisGastrointestinal disorders | 0/64 | 10/32 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 0/64 | 10/32 |
| FatigueGeneral disorders | 17/64 | 8/32 |
| DyspepsiaGastrointestinal disorders | 3/64 | 7/32 |
| VomitingGastrointestinal disorders | 10/64 | 6/32 |
| Decreased appetiteMetabolism and nutrition disorders | 12/64 | 6/32 |
| AnaemiaBlood and lymphatic system disorders | 4/64 | 5/32 |
| HypothyroidismEndocrine disorders | 2/64 | 5/32 |
Treated set: all patients who were dispensed trial medication and were documented to have taken at least 1 dose of investigational treatment.
| Age, Continuous(Years) | Nintedanib (BIBF 1120) | Sunitinib | Total |
|---|---|---|---|
| Mean | 60.4 ± 9.7 | 55.5 ± 11.4 | 58.8 ± 10.5 |
| Sex: Female, Male(Participants) | Nintedanib (BIBF 1120) | Sunitinib | Total |
|---|---|---|---|
| Female | 20 | 10 | 30 |
| Male | 44 | 22 | 66 |
| Race (NIH/OMB)(Participants) | Nintedanib (BIBF 1120) | Sunitinib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 64 | 32 | 96 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| QTcF interval baseline values(millisecconds (ms)) | Nintedanib (BIBF 1120) | Sunitinib | Total |
|---|---|---|---|
| -5 minutes | 405.2 ± 19.6 | — | 405.2 ± 19.6 |
| 1 hour (h) | 406.0 ± 20.3 | — | 406.0 ± 20.3 |
| 2 h | 405.3 ± 19.4 | — | 405.3 ± 19.4 |
| 3 h | 406.7 ± 19.4 | — | 406.7 ± 19.4 |
| 4 h | 407.0 ± 17.8 | — | 407.0 ± 17.8 |
| 5 h | 407.2 ± 18.0 | — | 407.2 ± 18.0 |
| 6 h | 405.9 ± 18.3 | — | 405.9 ± 18.3 |
| 7 h | 405.4 ± 19.2 | — | 405.4 ± 19.2 |
| 10 h | 406.6 ± 19.2 | — | 406.6 ± 19.2 |
| 12 h | 406.0 ± 19.2 | — | 406.0 ± 19.2 |
The record gives a start of Dec 2009, a primary completion of Nov 2011 and a completion of Jun 2020. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2020, 8 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib